3 completed, 1 terminated. 3 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 3 |
| Phase 2 | 2 | Completed 1, Terminated 1 |
Follow TargeGen: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Dose-escalation Study of the Safety and Tolerability of Orally Administered TG101348 in Patients With Myelofibrosis TG101348 - Myelofibrosis | Phase 1 | Completed | TargeGen | 59 | 2008-01-01 | 2009-10-26 |
| Open-Label, Pilot Study of TG100801 in Patients With Choroidal Neovascularization Due to AMD TG100801 - Macular Degeneration, Choroidal Neovascularization | Phase 2 | Terminated | TargeGen | 7 | 2007-07-01 | 2010-03-29 |
| A Phase 1 Safety Study of TG100801 Eye Drops in Healthy Volunteers TG100801 - Macular Degeneration, Diabetic Retinopathy | Phase 1 | Completed | TargeGen | 44 | 2006-11-01 | 2007-07-30 |
| Safety of TG100-115 for Heart Attack Treated With Angioplasty TG100-115 - Myocardial Infarction | Phase 1 / Phase 2 | Completed | TargeGen | 100 | 2005-01-01 | 2008-05-20 |
Macular Degeneration (2) · Choroidal Neovascularization (1) · Diabetic Retinopathy (1) · Macular Edema (1) · Myocardial Infarction (1) · Primary Myelofibrosis (1) · Retinal Diseases (1) · Vascular Diseases (1)
4-chloro-3-(5-methyl-3-((4-(2-pyrrolidin-1-ylethoxy)phenyl)amino)-1,2,4-benzotriazin-7-yl)phenol (2) · 3-(2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl)phenol (1) · fedratinib (1)
United States (4)
Ayalew Tefferi, MD (1) · Peter Kaiser, M.D. (1) · Philip T Leese, M.D. (1)